Abstract
This review provides evidence that antenatal hypoxia, which represents a significant and worldwide problem, causes prenatal programming of the lung. A general overview of lung development is provided along with some background regarding transcriptional and signaling systems of the lung. The review illustrates that antenatal hypoxic stress can induce a continuum of responses depending on the species examined. Fetuses and newborns of certain species and specific human populations are well acclimated to antenatal hypoxia. However, antenatal hypoxia causes pulmonary vascular disease in fetuses and newborns of most mammalian species and humans. Disease can range from mild pulmonary hypertension, to severe vascular remodeling and dangerous elevations in pressure. The timing, length, and magnitude of the intrauterine hypoxic stress are important to disease development, however there is also a genetic-environmental relationship that is not yet completely understood. Determining the origins of pulmonary vascular remodeling and pulmonary hypertension and their associated effects is a challenging task, but is necessary in order to develop targeted therapies for pulmonary hypertension in the newborn due to antenatal hypoxia that can both treat the symptoms and curtail or reverse disease progression.
Keywords: Hypoxia, pulmonary hypertension, sheep, fetal programming, newborns.
Current Vascular Pharmacology
Title:Antenatal Hypoxia and Pulmonary Vascular Function and Remodeling
Volume: 11 Issue: 5
Author(s): Demosthenes G. Papamatheakis, Arlin B. Blood, Joon H. Kim and Sean M. Wilson
Affiliation:
Keywords: Hypoxia, pulmonary hypertension, sheep, fetal programming, newborns.
Abstract: This review provides evidence that antenatal hypoxia, which represents a significant and worldwide problem, causes prenatal programming of the lung. A general overview of lung development is provided along with some background regarding transcriptional and signaling systems of the lung. The review illustrates that antenatal hypoxic stress can induce a continuum of responses depending on the species examined. Fetuses and newborns of certain species and specific human populations are well acclimated to antenatal hypoxia. However, antenatal hypoxia causes pulmonary vascular disease in fetuses and newborns of most mammalian species and humans. Disease can range from mild pulmonary hypertension, to severe vascular remodeling and dangerous elevations in pressure. The timing, length, and magnitude of the intrauterine hypoxic stress are important to disease development, however there is also a genetic-environmental relationship that is not yet completely understood. Determining the origins of pulmonary vascular remodeling and pulmonary hypertension and their associated effects is a challenging task, but is necessary in order to develop targeted therapies for pulmonary hypertension in the newborn due to antenatal hypoxia that can both treat the symptoms and curtail or reverse disease progression.
Export Options
About this article
Cite this article as:
Papamatheakis G. Demosthenes, Blood B. Arlin, Kim H. Joon and Wilson M. Sean, Antenatal Hypoxia and Pulmonary Vascular Function and Remodeling, Current Vascular Pharmacology 2013; 11 (5) . https://dx.doi.org/10.2174/1570161111311050006
DOI https://dx.doi.org/10.2174/1570161111311050006 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Lack of Association Between Blood Glutamate and Anxiety Levels in Pre- delivery Pregnant Women
Current Pharmaceutical Analysis The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design Subject Index to Volume 4
Current Topics in Medicinal Chemistry Natriuretic Peptides in Heart Failure and Post-Myocardial Infarction
Current Hypertension Reviews Nutrition Communication in General Practice
Current Nutrition & Food Science Fenofibrate and Telmisartan in the Management of Abdominal Aortic Aneurysm
Current Drug Targets Alpha1-Antitrypsin Deficiency: Transition of Care for the Child With AAT Deficiency into Adulthood
Current Pediatric Reviews Soy Isoflavones and Cardiovascular Disease Epidemiological, Clinical and -Omics Perspectives
Current Pharmaceutical Biotechnology Metastasis-Inducing S100A4 Protein: Implication in Non-Malignant Human Pathologies
Current Molecular Medicine The Molecular Concept of Atheromatous Plaques
Current Drug Targets Refined Echocardiographic Assessment and Contemporary Medical Treatment of Obstructive Hypertrophic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Multiplex Analysis of Cardiac Hypertrophic Signaling: Reduced in vivo Phosphorylation of Glycogen Synthase Kinase-3β and Proline-Rich Akt Substrate (PRAS40)
Current Signal Transduction Therapy Heat Shock Proteins: Mediators of Atherosclerotic Development
Current Drug Targets ACE Inhibitor-Angiotensin Receptor Blocker Combinations: A Clinicians Perspective
Mini-Reviews in Medicinal Chemistry Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology Systemic Lupus Erythematosus-Related Interstitial Lung Disease
Current Rheumatology Reviews Developments in Imaging Technologies Related to Hypertensive Cardiovascular Diseases
Current Pharmaceutical Design